The synthesis of the series of pyrimidinylamines 1a-d and pyrimidinylureas 1e-u bearing a novel pyridinylcarbonylpyrimidine scaffold and their antiproliferative activities against A375 human melanoma cell line were described. Among them, three compounds 1e, 1h, and 1o showed superior antiproliferative activities to Sorafenib (IC 50 = 5.5 µM) as a reference compound. In our series, urea compound 1o having 4-chloro-3-trifluoromethyl moiety on the benzene nucleus exhibited very good antiproliferative activity with IC 50 value of 1.4 µM.
Introduction
Melanoma is a malignant tumor that arises from melanocytic cells and primarily involves the skin. Incidence of melanoma has tripled in the last 40 years, and more than 80% of skin cancer deaths are due melanoma. Generally, two major risk factors for melanoma development are an individual's family history and an environmental factor. The most relevant environmental factor is exposure to solar ultraviolet irradiation that causes damage to the DNA of cells.
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In early-stage melanoma without metastasis, treatment for localized melanoma normally involves surgery to remove the lesion. Melanomas can metastasize either by the lymphatic or by the hematogenous route. 2 The 5-year survival rate for patients with metastatic melanoma below 15% and median survival of about 6-8 months.
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Decarbazine (DTIC) 7, 8 is the only cytotoxic agent formally approved for the treatment of melanoma and Temozolomide (Temodar) 9 is an imidazotetrazine with a mechanism of action similar to DTIC. Both of them are used most frequency for stage IV melanoma patients as a chemotherapy. The current treatments involve surgical removal of the tumor, immunotherapy, radiotherapy, chemotherapy, various combinations. However, due to the development of metastatic disease which is highly resistant to conventional chemotherapeutics and radiation, 10 the intensive research and effort into new drugs and treatments [11] [12] [13] [14] [15] [16] [17] [18] [19] for new targeted therapy and advanced melanoma have not afforded the effective response rates yet.
In this paper, based on the structural features of Sorafenib (Nexavar) 20 that has been used extensively in clinical trials, a novel scaffold having pyridinylcarbonylpyrimidine group by the introduction of pyridinyl and pyrimidine moieties as hinge and linker was designed as shown in Figure 1 . We report here the synthesis of pyrimidinylamine derivatives 1a-d and pyrimidinylurea derivatives 1e-u, and their antiproliferative activities against A375 human melanoma cell line compared with Sorafenib.
Results and Discussion
Chemistry. Pyridinylcarbonylpyrimidine derivatives 1a-d with amine moiety were prepared by the sequence outlined in Scheme 1.
Amidation of carboxylic acid group of nicotinic acid (2) as a starting material with N,O-dimethylhydroxylamine hydrochloride in the presence of HOBt, EDCI, and triethylamine gave N-methoxy-N-methylamide (Weinreb amide) 3, which was then coupled with 2-iodo-4-methylthiopyrimidine (5) using i-PrMgCl to give methylthiopyrimidine 6.
21 Conversion of chloro group of 2-chloro-4-methylthiopyrimidine (4) to iodo group with HI provided the desired compound 5 in good yield. 22 Oxidation of 6 with oxone in MeOH 23 and subsequent amination of the resulting 7 with the appropriate formamides 9a-d in the presence of NaH afforded the corresponding pyrimidinylformamides 10a-d, respectively. Formamides 9a-d were obtained from the corresponding amines 8a-d by formylation using formic acid and ZnO, respectively. 23 The title compounds 1a-d were obtained by hydrolysis of formyl group using 3 M NaOH.
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The synthesis of pyridinylcarbonylpyrimidine derivatives 1e-u having urea moiety was outlined in Scheme 2.
Amidation of methylsulfonylpyrimidine 7 with ammonia solution in isopropyl alcohol using a sealed tube gave aminopyrimidine 11, 25 which was reacted with the appropriate isocyanates in pyridine to afford the corresponding title compounds 1e-u, respectively.
Biological Evaluation. Table 1 and 2 show the in vitro antiproliferative activities (IC 50 values) of pyrimidinylamines 1a-d and pyrimidinylureas 1e-u against A375 human melanoma cell line together with that of Sorafenib as a reference compound.
All the synthesized compounds were evaluated by MTT assays using CellTiter 96 ® (Promega) and the results are summarized in Table 1 and 2. All the amine compounds did not show any significant activities. Generally, urea compounds 1e-u possessed more potent activities as compared to amine compounds 1a-d. Urea compound 1o with 4-chloro-3-trifluoromethyl moiety showed better antiproliferative activity than the corresponding amine compound 1b. As shown in Table 2 , three compounds 1e, 1h, and 1o showed superior antiproliferative activity against A375 human melanoma cell line to Sorafenib. Among them, compound 1o bearing 4-chloro-3-trifluoromethyl moiety exhibited very good antiproliferative activity with IC 50 value of 1.4 μM. In general, compounds 1e, f, h, j, o, p having electron-withdrawing groups on the benzene nucleus possessed better activities compared to compounds 1l-n, q with electron-donating groups. The bulkier substituents in compounds 1q-t did not give the positive effect to antiproliferative activity.
There are identified mutations in the RasRaf/MAPK pathway in over 80% of cases of melanoma. The commonest of these somatic mutations is the V600E mutation in b-Raf. The representative compound 1o was screened against V600E-b-Raf enzyme to identify Ras/Raf/MAPK pathway using HotSpot kinase assay by Reaction Biology Corp.. Compound 1o showed the marginal inhibitory activity with IC 50 value of 61.9 μM against mutant b-Raf enzyme. Veri- fication of mode of action is under way.
In conclusion, a novel scaffold having pyridinylcarbonylpyrimidine group based on the structural features of Sorafenib was designed. In our series, pyrimidinylurea compounds 1e, 1h, and 1o exhibited superior antiproliferative activity against A375 human melanoma cell line to Sorafenib. These results suggest that pyridinylcarbonylpyrimidine group has potentials as a scaffold for treatment of melanoma.
Experimental Section
General.
1

H NMR and
13
C NMR spectra were recorded on a Bruker Avance 400 spectrometer (400 MHz for 1 H and 100 MHz for 13 C) using tetramethylsilane as an internal standard. LC-Mass spectra were determined on a Waters Quattro Micro system. Column chromatography was carried out using silica gel (230-400 mesh). Solvents and liquid reagents were transferred using hypodermic syringes. All solvents and reagents were commercially available and used without further purification.
N-Methoxy-N-methylnicotinamide (3). To a solution of nicotinic acid (2) (500 mg, 3.62 mmol), N,O-dimethylhydroxylamine hydrochloride (458 mg, 4.7 mmol), HOBt (364 mg, 4.7 mmol), and EDCI (1.04 g, 5.43 mmol) in DMF was added triethylamine (2.5 mL, 18.1 mmol). The mixture was stirred at 90 o C for 18 h. Upon completion, the reaction mixture was treated with 10% NaHCO 3 . The resulting solution was extracted with ethyl acetate. The organic layer was dried over anhydrous MgSO 4 , and then evaporated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/n-hexane, 2/1, v/v) to give the compound 3 (528 mg, 81% yield). (2-Methylthiopyrimidin-4-yl)(pyridin-3-yl)methanone (6) . To a solution of 2-iodo-4-methylthiopyrimidine (5) (1.82 g, 7.22 mmol) in dry toluene at 0 o C was added isopropyl magnesium chloride (2 M in THF) (4.15 mL, 9.03 mmol) dropwise. The mixture was stirred at the same temperature for 1 h, and then compound 3 was added and the resulting mixture was stirred at room temperature for 10 h. Upon completion, the reaction was quenched with NH 4 Cl solution and extracted with ethyl acetate. The organic layer was dried over anhydrous MgSO 4 , and then evaporated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/n-hexane, 2/1, v/v) to give the compound 6 (552 mg, 38% yield). (2-Methylsulfonylpyrimidin-4-yl)(pyridin-3-yl)methanone (7) . To a solution of compound 6 (400 mg, 1.72 mmol) in MeOH at 0 o C was added oxone (1.06 g, 1.72 mmol) and water. The mixture was stirred at room temperature for 5 h. Upon completion, the reaction mixture was extracted with chloroform. The organic layer was dried over anhydrous MgSO 4 , and then evaporated under reduced pressure to give the compound 7 (209 mg, 46% yield). N-(2,4-Dimethylphenyl)-N-(4-nicotinoylpyrimidin-2-yl)-formamide (10a). To a stirred solution of sodium hydride (60% dispersion in mineral oil) (20 mg, 0.86 mmol) in dry THF was added N-(2,4-dimethylphenyl)formamide (9a) (101 mg, 0.68 mmol). The mixture was refluxed for 30 min, and then compound 7 was added and the resulting mixture General Procedure for the Synthesis of (2-substituted aminopyrimidin-4-yl)(pyridin- 
2-Iodo-4-methylthiopyrimidine (5).
2-Chloro-4-methylthiopyrimidine (4) (1.0 g, 6.2 mmol) was added to hydriodic acid (47%) (10 mL) at 0 o C, and the mixture was stirred at room temperature for 18 h. Upon completion, the reaction mixture was neutralized with NaOH solution and extracted with methylene chloride. The organic layer was dried over anhydrous MgSO 4 , and then evaporated under reduced pressure to give the compound 5 (1.2 g, 78% yield). (2-Aminopyrimidin-4-yl)(pyridin-3-yl)methanone (11). Compound 7 (196 mg, 0.75 mmol) was added to ammonia (2 M solution in isopropyl alcohol) (1.9 mL, 3.75 mmol), and the mixture was stirred at 70 o C for 10 h. After the reaction completed, the solvent was removed under reduced pressure. The reaction mixture was treated with water and methylene chloride. The organic layer was dried over anhydrous MgSO 4 , and then evaporated under reduced pressure to give the compound 11 (1.2 g, 48% yield). General Procedure for the Synthesis of 1-substituted 3-(4-nicotinoylpyrimidin-2-yl)ureas 1e-u. To a solution of compound 11 (0.175 mmol) in pyridine was added the appropriate isocyanate compound (1.75 mmol), and the mixture was refluxed for 10 h. Upon completion, the reaction mixture was treated with 10% NaHCO 3 . After the reaction completed, pyridine was distilled off. The residue was purified by silica gel column chromatography (ethyl acetate/nhexane, 2/1, v/v) to give the title compound 1.
1-(2-Chlorophenyl)-3-(4-nicotinoylpyrimidin-2-yl)urea (1e). Yield 21%; ® (Promega) according to the manufacturer's instructions. The absorbance at 590 nm was recorded using EnVision 2103 (Perkin Elmer; Boston, MA, US). The IC 50 was calculated using GraphPad Prism 4.0 software.
